Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Philadelphia, Pennsylvania

This page shows live ClinicalTrials.gov search results for Philadelphia, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
17144
Shown on this page
12
Current sort
Recently updated
Location scope
Philadelphia, PA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Philadelphia, Pennsylvania. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 481–492 of 17,144 matching trials in Philadelphia, PA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Philadelphia

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Completed Phase 2 Interventional Results available

Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

NCT03864068
Conditions
Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
Interventions
Placebo, Inositol
Other · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Verducatib, Placebo matching verducatib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Palma, California + 14 more
Conditions
Tuberculosis, Pulmonary
Interventions
[18F]-FAPI-74
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Advanced Solid Tumour
Interventions
BI 3968621, ezabenlimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Sarasota, Florida • Atlanta, Georgia • Philadelphia, Pennsylvania + 2 more
Conditions
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions
Atumelnant, Placebo
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 12 more
Conditions
Major Depressive Disorder
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
35
States / cities
Phoenix, Arizona • Chino, California • Montclair, California + 28 more
Conditions
Amyotrophic Lateral Sclerosis
Interventions
INS1202
Genetic
Lead sponsor
Insmed Gene Therapy LLC
Industry
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Phoenix, Arizona • La Jolla, California • Palo Alto, California + 6 more
Conditions
Autoimmune Lymphoproliferative Syndrome
Interventions
Soquelitinib
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania • Houston, Texas
Conditions
Multiple Myeloma
Interventions
Teclistamab, Lenalidomide
Drug
Lead sponsor
European Myeloma Network B.V.
Network
Eligibility
18 Years and older
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
39
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more
Conditions
Respiratory Failure, Premature Neonates, Delivery Room Resuscitation, Positive Pressure Ventilation, Neonatal Resuscitation, Supraglottic Airway, Laryngeal Mask, Laryngeal Mask Airways
Interventions
Supraglottic Airway
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
0 Days to 1 Day
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Violence, Substance Use, Criminal Behavior, Violence in Adolescence
Interventions
Remote Therapy Intervention (RTI), Artificial Intelligence Remote Therapy Intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
14 Years to 24 Years
Enrollment
584 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Detroit, Michigan • Flint, Michigan + 1 more
Conditions
Chronic Kidney Disease
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 17 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 22 more